Compare AstraZeneca plc (AZN) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Essex Property Trust, Inc. — how do they compare? AstraZeneca plc trades at $167 (market cap $253.13B), while Essex Property Trust, Inc. trades at $297.8 (market cap $19.16B). The key difference: AstraZeneca plc is far larger — about 13.2× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| AZN | ESS | |
|---|---|---|
Market Cap | $253.13B | $19.16B |
Sector | Health | Real Estate |
52-Week High | $209.48 | $298.33 |
52-Week Low | $137.44 | $239.61 |
Enterprise Value | $279.37B | $25.88B |
Dividend Yield | 1.92% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
ESS trades at $297.48, up 1.34% today, near its consensus price target of $294.25. The stock shows bullish technical momentum with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and the company's addition to the Russell Microcap Index. Fundamentals remain solid with $1.89B revenue and a 30.03% net income margin in 2025.
Outlook is cautiously optimistic given analyst consensus leaning toward Hold (52.17%) despite recent beats. Key opportunities include AI-driven rental demand in West Coast markets and a sustainable dividend. Risks involve high debt levels (debt-to-asset ratio of 51.92% in 2024) and potential economic sensitivity. The stock offers moderate upside if earnings momentum continues but requires monitoring of leverage and regional market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
